New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2013
07:38 EDTARWRArrowHead begins phase 1 trial of ARC-520 for Hepatitis B infection treatment
Arrowhead Research announced that it has initiated dosing in a Phase 1 clinical trial of ARC-520, the company’s candidate for the treatment of chronic hepatitis B virus infection. Trial initiation followed successful completion of the Clinical Trial Notification regulatory process in Australia. The objectives of the study are to characterize the safety profile of ARC-520, determine maximum tolerated dose, and evaluate pharmacokinetics in healthy volunteers.The Phase 1 trial is a single-center, randomized, double-blind, placebo-controlled, single dose-escalation, first-in-human study of ARC-520 administered intravenously to healthy adult volunteers and is being conducted in Melbourne, Australia. Each dose cohort includes 6 subjects randomized at ratio of 1:2 to receive a single intravenous injection of either placebo or ARC-520. Arrowhead expects to complete this Phase 1 trial in Q4 and begin a Phase 2a trial in chronic HBV patients in 2014.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
10:37 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 15, 2015
10:20 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP RAX KING AOL WPZ RL Z MBI
May 14, 2015
10:56 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
May 13, 2015
11:08 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
May 12, 2015
10:16 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: NDLS WTW FUEL AOL LC NLNK ZU CYBR ARWR HZNP
May 11, 2015
16:09 EDTARWRArrowhead reports Q2 EPS (51c), consensus (34c)
Reports Q2 revenue $43,750, consensus $110,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use